



16 June 2020

Company Announcements Office
Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney NSW 2000

Dear Sir / Madam

NOTICE UNDER SECTIONS 7(f) OF THE ASIC CORPORATIONS (SHARE AND INTEREST PURCHASE PLANS) INSTRUMENT 2019/547 AND 708A(5)(e) OF THE CORPORATIONS ACT

Further to the ASX announcement made by Medlab Clinical Limited (**Company**) (ASX: MDC) on 15 June 2020, the Company has announced the proposed issue of 26,666,666 fully paid ordinary shares (**Shares**) under a Share Purchase Plan.

The Company advises that the Corporations Act 2001 (Cth) (**Corporations Act**) restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or section 708A.

This notice is given by the Company under section 7(f) of the ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 and section 708A(5)(e) of the Corporations Act and advises:

1. the Company will issue the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of the notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Act as they apply to the Company; and
 - b. section 674 of the Corporations Act as it applies to the Company;
3. as at today's date, there is no information that is excluded information which is required to be set out in this notice pursuant to section 708A(7) and 708A(8) of the Act.

For and behalf of the Board.

Alan Dworkin
Company Secretary